Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study

格列美脲 利拉鲁肽 二甲双胍 医学 2型糖尿病 安慰剂 减肥 内科学 联合疗法 糖尿病 胃肠病学 内分泌学 泌尿科 肥胖 替代医学 病理
作者
Michael A. Nauck,Anders Frid,Kjeld Hermansen,Anne Bloch Thomsen,Maria Düring,Nasir Shah,Tsvetalina Tankova,Ismail Mitha,David R. Matthews
出处
期刊:Diabetes, Obesity and Metabolism [Wiley]
卷期号:15 (3): 204-212 被引量:123
标识
DOI:10.1111/dom.12012
摘要

Aims To investigate efficacy and safety of dual therapy with liraglutide and metformin in comparison to glimepiride and metformin, and metformin monotherapy over 2 years in patients with type 2 diabetes. Methods In the 26-week the Liraglutide Effect and Action in Diabetes (LEAD)-2 core trial, patients (n = 1091) were randomized (2 : 2 : 2 : 1: 2) to liraglutide (0.6, 1.2 or 1.8 mg once-daily), placebo or glimepiride; all with metformin. Patients were enrolled if they were 18–80 years old with HbA1c 7.0–11.0% (previous monotherapy ≥3 months), or 7.0–10.0% (previous combination therapy ≥3 months), and body mass index ≤40 kg/m2. Patients completing the 26-week double-blinded phase could enter an 18-month open-label extension. Results HbA1c decreased significantly with liraglutide (0.4% with 0.6 mg, 0.6% with 1.2 and 1.8 mg) versus 0.3% increase with metformin monotherapy (p < 0.0001). HbA1c decrease with liraglutide was non-inferior versus 0.5% decrease with glimepiride. Liraglutide groups experienced significant weight loss (2.1, 3.0 and 2.9 kg with 0.6, 1.2 and 1.8 mg, respectively) compared to weight gain (0.7 kg) with glimepiride (p < 0.0001). Weight loss with liraglutide 1.2 and 1.8 mg was significantly greater than with metformin monotherapy (1.8 kg; p = 0.0185 and p = 0.0378 for 1.2 and 1.8 mg, respectively). The occurrence of minor hypoglycaemia was <5.0% in all liraglutide groups, significantly less than with glimepiride (24.0%; p < 0.0001). Liraglutide was well tolerated overall: gastrointestinal events were more common than with glimepiride or metformin monotherapy, but occurrence decreased with time. Conclusions Liraglutide provided sustained glycaemic control over 2 years comparable to that provided by glimepiride. Liraglutide was well tolerated, and was associated with weight loss and a low rate of hypoglycaemia.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
伤逝1990完成签到,获得积分10
1秒前
zz完成签到,获得积分10
1秒前
科研韭菜发布了新的文献求助30
2秒前
2秒前
李爱国应助AaronDP采纳,获得10
2秒前
4秒前
玛卡巴卡发布了新的文献求助10
5秒前
风趣的老太应助安静明杰采纳,获得10
6秒前
水论文行者完成签到,获得积分10
7秒前
8秒前
cola应助亿亿亿亿采纳,获得10
9秒前
BioGO完成签到,获得积分10
9秒前
10秒前
10秒前
大模型应助M1有光采纳,获得10
11秒前
11秒前
11秒前
rrrrrrry发布了新的文献求助10
11秒前
12秒前
12秒前
共享精神应助李凌霄采纳,获得10
12秒前
lu发布了新的文献求助10
14秒前
跳跃的乌龟完成签到,获得积分10
15秒前
xww完成签到,获得积分10
15秒前
白桦林泪发布了新的文献求助10
16秒前
16秒前
俏皮瑾瑜发布了新的文献求助10
17秒前
lulu发布了新的文献求助20
17秒前
杰2580发布了新的文献求助10
17秒前
英俊的铭应助澡雪采纳,获得10
19秒前
19秒前
年轻半雪发布了新的文献求助10
19秒前
19秒前
脑洞疼应助有点is采纳,获得10
20秒前
安的沛白发布了新的文献求助10
21秒前
郭小燕发布了新的文献求助10
21秒前
江风海韵完成签到,获得积分10
21秒前
22秒前
钙离子发布了新的文献求助10
24秒前
乔乔兔应助cccccc采纳,获得20
25秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Effective Learning and Mental Wellbeing 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975871
求助须知:如何正确求助?哪些是违规求助? 3520207
关于积分的说明 11201502
捐赠科研通 3256611
什么是DOI,文献DOI怎么找? 1798403
邀请新用户注册赠送积分活动 877552
科研通“疑难数据库(出版商)”最低求助积分说明 806430